ATOM

Valour Inc. Announces Filing of a New EU-Base Prospectus

Retrieved on: 
Friday, October 28, 2022
Newton, Cardano, Carbon, Zero, Ethereum, NEO, Company, BTC, EU, ETP, BNB, Growth, ADA, CEO, Adoption, Inc., Decentralized finance, ENJ, View, SOL, ATOM, The Company, OTC, Multimedia, Legislation, ETH, UNI, AVAX, DOT, SFSA, Security (finance), Cryptocurrency, Bitcoin, Cosmos, Polka dot, Courage

"As digital assets enter the mainstream and reshape the financial ecosystem we intend to integrate creative solutions and expand upon our low fee product offerings, said Olivier Roussy Newton, CEO of Valour.

Key Points: 
  • "As digital assets enter the mainstream and reshape the financial ecosystem we intend to integrate creative solutions and expand upon our low fee product offerings, said Olivier Roussy Newton, CEO of Valour.
  • Valour offers fully hedged digital asset ETPs with low to zero management fees, with product listings across European exchanges, banks and broker platforms.
  • Valour's existing product range includes Valour Uniswap ( UNI ), Cardano ( ADA ), Polkadot ( DOT ), Solana ( SOL ), Avalanche ( AVAX ), Cosmos ( ATOM ), Binance ( BNB ), Enjin ( ENJ ), Valour Bitcoin Carbon Neutral , and Valour Digital Asset Basket 10 ( VDAB10 ) ETPs with low management fees.
  • Founded in 2019, Valour is backed by an acclaimed and pioneering team with decades of experience in financial markets and digital assets.

PingPod 24/7 Ping Pong Concept Plans Nationwide Expansion with SiteSeer Pro

Retrieved on: 
Friday, October 21, 2022
Silberman, CFO, City, VP, Lower East Side, LLC, Research, Software, ATOM, Tennis, Video game

BOISE, Idaho, Oct. 21, 2022 /PRNewswire-PRWeb/ -- SiteSeer Technologies, creator of SiteSeer Professional site selection software and Void Analysis Pro is pleased to welcome a new client, PingPod. PingPod is a fully automated, 24/7 ping pong concept where casual and competitive players alike can reserve table tennis "pods" through PingPod's proprietary app and play for 30-minute increments.

Key Points: 
  • SiteSeer Technologies, creator of SiteSeer Professional site selection software and Void Analysis Pro is pleased to welcome a new client, PingPod.
  • BOISE, Idaho, Oct. 21, 2022 /PRNewswire-PRWeb/ -- SiteSeer Technologies, creator of SiteSeer Professional site selection software and Void Analysis Pro is pleased to welcome a new client, PingPod.
  • PingPod is a fully automated, 24/7 ping pong concept where casual and competitive players alike can reserve table tennis "pods" through PingPod's proprietary app and play for 30-minute increments.
  • Sam Lowder, VP of business development for SiteSeer Technologies, says that SiteSeer is excited to support PingPod in its growth story.

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

EVgo and Warner Bros. Pictures Join Forces to Invite EV Drivers to See the Electrifying Power of BLACK ADAM

Retrieved on: 
Tuesday, October 11, 2022
Film & Motion Pictures, Alternative Energy, Energy, Alternative Vehicles, Fuels, Automotive, Technology, Other Technology, Entertainment, Work, IMAX, CYCLONE, DC, Black Adam, Transport, Fandango Media, Electricity, RFID, Organization, NASDAQ, Fandango, BLACK, Code, Lightning, Multimedia, Partnership, EVS, EV, DOCTOR, Warner Bros. Pictures, ATOM, DC Super Hero Girls (TV series), Travel, Name, Solution, Television, NRG Energy

In partnership with BLACK ADAM, EVgo account holders will be eligible for a $5 Fandango Promotional Code* after completing a qualifying charging session** at an EVgo station.

Key Points: 
  • In partnership with BLACK ADAM, EVgo account holders will be eligible for a $5 Fandango Promotional Code* after completing a qualifying charging session** at an EVgo station.
  • Drivers in the area will be able to power up with one of their favorite DC Super Heroes from the upcoming film: BLACK ADAM, HAWKMAN, DOCTOR FATE, CYCLONE or ATOM SMASHER.
  • BLACK ADAM decals will also be featured at select stations across the U.S. with a QR code where customers can watch the BLACK ADAM trailer while charging.
  • With over 850 fast charging locations and 1,000+ L2 chargers nationwide, EVgo customers across the U.S. are eligible for electric savings to see BLACK ADAM.

Valour Announces Debut of Bitcoin Carbon Neutral Exchange Traded Product (ETP) on Börse Frankfurt

Retrieved on: 
Friday, September 23, 2022
Carbon, Crypto, Zero, Cardano, Ethereum, AVAX, Patch, Adoption, ATOM, UNI, BNB, ESG, Efficiency, ISIN, ETP, DOT, BTC, Gold standard, ADA, Legislation, ETH, Growth, ENJ, Mining, Decentralized finance, Environment, Investment, Phrase, OTC, CEO, NEO, NGM, Puro, Goal, API, Ecosystem, SOL, Multimedia, Cryptocurrency, Issuer, Polka dot, Cosmos, Bitcoin, Courage, Euronext

Valour Bitcoin Carbon Neutral offers investors exposure to Bitcoin and presents a trusted investment method that benefits the environment and aligns with ESG goals by funding certified carbon removal and offset initiatives in order to neutralise the associated Bitcoin carbon footprint.

Key Points: 
  • Valour Bitcoin Carbon Neutral offers investors exposure to Bitcoin and presents a trusted investment method that benefits the environment and aligns with ESG goals by funding certified carbon removal and offset initiatives in order to neutralise the associated Bitcoin carbon footprint.
  • Starting today, September 23, investors in Germany will be able to purchase the Bitcoin Carbon Neutral ETP (ISIN: CH1149139706) with a low management fee of 1.49% on Brse Frankfurt, the largest exchange in Germany.
  • TORONTO, Sept. 23, 2022 /PRNewswire/ -Valour Inc. (the "Company" or "Valour") (NEO: DEFI) (GR: RMJR) (OTC: DEFTF), a technology company and the first and only publicly traded company that bridges the gap between traditional capital markets, Web3 and decentralised finance, announced that it will debut its new Carbon Neutral Bitcoin Exchange Traded product ("ETP") on Brse Frankfurt.
  • Valour Bitcoin Carbon Neutral ETP (ISIN: CH1149139706) provides investors with sustainable and climate-friendly exposure to Bitcoin with a low management fee of 1.49%.

stackArmor Achieves AWS Security and AWS Level 1 MSSP Competencies

Retrieved on: 
Tuesday, September 13, 2022
Security, White House, Federal Government, Technology, Public Policy, Government, Software, Zero, Amazon Web Services, ATOM, Time, CMMC, NIST, FISMA, AWS, MSSP, Privacy, Public sector, Organization, Compliance, APN, Defense, CSPM, Technology, Competence, DOD, Goal, Red Hat, Solution, ATO, SSE, Government, Security Service, Education, Amazon, Online shopping, Risk management, Forging, FedRAMP, Forcepoint, Health care

stackArmor also announced it has achieved AWS Level 1 Managed Security Service Provider (MSSP) Competency status.

Key Points: 
  • stackArmor also announced it has achieved AWS Level 1 Managed Security Service Provider (MSSP) Competency status.
  • AWS launched the AWS Level 1 MSSP Competency to enable customers to easily acquire ongoing security monitoring and management, validated by AWS.
  • AWS security experts annually validate the tools used and operational processes of each MSSP address specific cloud security challenges such as continuous event monitoring, triaging, AWS service configuration best practices, and 24/7 incident response.
  • Achieving both, AWS Security and AWS Level 1 MSSP competencies differentiates stackArmor as an MSSP and AWS Partner that provides specialized consulting services designed to help companies from startups and mid-sized businesses to the largest global enterprises to adopt, develop and deploy complex security projects on AWS with essential 24/7 managed cloud security skillsets.

Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development

Retrieved on: 
Thursday, September 8, 2022
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Artificial Intelligence, Machine learning, Partnership, Contract, Technology, Research, Strategic partnership, Spatial analysis, FS, Precision medicine, Decision-making, ATOM, Infection, Pathology, CD38, Laboratory, Neuroscience, Multimedia, IHC, Na+/K+-ATPase, Immune system, H&E, Biomarker, Neoplasm, Drug discovery, Medical imaging

This strategic partnership will allow us to utilize multiplex technology and provide a complete, actionable, and scalable solution to improve drug target discovery and development of our pharma and biotech partners.

Key Points: 
  • This strategic partnership will allow us to utilize multiplex technology and provide a complete, actionable, and scalable solution to improve drug target discovery and development of our pharma and biotech partners.
  • Our partnership with Nucleai is based on our shared vision to advance next-generation spatial multiplex immunofluorescence imaging to accelerate drug and biomarker discovery and development, said Dborah Heintze, Chief Marketing Officer of Lunaphore.
  • Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory.
  • Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data.

DGAP-News: Media and Games Invest: Strong Q2’22 with 37% Overall and 18% Organic Revenue Growth. Confirmation of Guidance 2022. Focusing on Organic Growth, Increasing Profitability as well as Deleveraging

Retrieved on: 
Wednesday, August 31, 2022
ISIN, KingsIsle Entertainment, Yoy, EBITDA, Loïc Le Meur, Segment, Revenue, EBIT, OTCQX, Moment, ATOM, EUR, Organic growth, Company, EPS, Acquisition, Online gambling, Lobster, Pet, Medical device, Video game, Life insurance

Media and Games Invest: Strong Q222 with 37% Overall and 18% Organic Revenue Growth.

Key Points: 
  • Media and Games Invest: Strong Q222 with 37% Overall and 18% Organic Revenue Growth.
  • Focusing on Organic Growth, Increasing Profitability as well as Deleveraging
    The issuer is solely responsible for the content of this announcement.
  • Media and Games Invest: Strong Q222 with 37% Overall and 18% Organic Revenue Growth.
  • Focusing on Organic Growth, Increasing Profitability as well as Deleveraging
    Net Revenues amounted to 78.1 mEUR in Q2'22 (Q221: 57.1 mEUR), which is an increase of 37%, whereof 18% were driven by Organic Revenue Growth1.

Media and Games Invest: Strong Q2’22 with 37% Overall and 18% Organic Revenue Growth. Confirmation of Guidance 2022. Focusing on Organic Growth, Increasing Profitability as well as Deleveraging

Retrieved on: 
Wednesday, August 31, 2022
ISIN, KingsIsle Entertainment, Yoy, EBITDA, Loïc Le Meur, Segment, Revenue, EBIT, OTCQX, Moment, ATOM, EUR, Organic growth, Company, EPS, Acquisition, Online gambling, Lobster, Pet, Medical device, Video game, Life insurance

Media and Games Invest: Strong Q222 with 37% Overall and 18% Organic Revenue Growth.

Key Points: 
  • Media and Games Invest: Strong Q222 with 37% Overall and 18% Organic Revenue Growth.
  • Focusing on Organic Growth, Increasing Profitability as well as Deleveraging
    Media and Games Invest: Strong Q222 with 37% Overall and 18% Organic Revenue Growth.
  • Focusing on Organic Growth, Increasing Profitability as well as Deleveraging
    Net Revenues amounted to 78.1 mEUR in Q2'22 (Q221: 57.1 mEUR), which is an increase of 37%, whereof 18% were driven by Organic Revenue Growth1.
  • EBITDA2 amounted to 21.1 mEUR in Q2'22 (Q221: 15.3 mEUR), which is an increase of 38%.